Alkermes Plc (ALKS) Stock AnalysisALKSAlkermes Plc

Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alkermes appears to be a good buy right now due to its strong revenue growth, with a reported $888.9 million in revenue for the first half of 2026, a 27.5% increase year-over-year, and a favorable analyst outlook with a median price target of $59. However, the main risk is the recent insider selling, where the Chief Commercial Officer sold 7,576 shares, reducing his holdings by 7%, which may indicate some caution among insiders.

12 analysts cover ALKS: 5 rate it Buy, 7 Hold and 0 Sell. The average price target is 46.20.